The Carlyle Group Inc. (NASDAQ:CG) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Daniel Harris - Head, IR Harvey Schwartz - CEO John Redett - CFO and Head, Corporate Strategy Conference Call Participants Alex Blostein - Goldman Sachs Ken Worthington - JPMorgan Ben Budish - Barclays Patrick Davitt - Autonomous Research Brian McKenna - Citizens GMP Glenn Schorr - Evercore ISI Mike Brown - Wells Fargo Securities Brian Bedell - Deutsche Bank Brennan Hawken - UBS Steven Chubak ...

NewtekOne, Inc. (NASDAQ:NEWT) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Barry Sloane - Founder, President and CEO Scott Price - Chief Financial Officer, NewtekOne and Newtek Bank National Association Nicolas Young - President and COO, Newtek Bank Conference Call Participants Crispin Love - Piper Sandler Tim Switzer - KBW Steve Moss - Raymond James Christopher Nolan - Ladenburg Thalmann & Co. Operator Good day and thank you for standing by. Welcome to the NewtekOne, In ...

TORM plc (NASDAQ:TRMD) Q3 2024 Earnings Conference Call November 7, 2024 9:00 AM ET Company Participants Jacob Meldgaard – Chief Executive Officer Kim Balle – Chief Financial Officer Conference Call Participants Emily Harkins – Jefferies Operator Hello, my name is Audra and I will be your conference operator today. At this time I would like to welcome everyone to the TORM Third Quarter 2024 Results Conference Call. Today’s conference is being recorded. All lines have been placed on mute to prevent any backg ...

BCE Inc. (NYSE:BCE) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Thane Fotopoulos - Investor Relations Mirko Bibic - President and CEO Curtis Millen - Chief Financial Officer Conference Call Participants Sebastiano Petti - JPMorgan Vince Valentini - TD Securities Drew McReynolds - RBC Capital Markets Maher Yaghi - Scotia Bank Simon Flannery - Morgan Stanley Aravinda Galappatthige - Canaccord Genuity Jerome Dubreuil - Desjardins Securities Batya Levi - UBS Lauren Bonham - ...

ArcelorMittal S.A. (NYSE:MT) Q3 2024 Earnings Conference Call November 7, 2024 9:30 AM ET Company Participants Daniel Fairclough – Investor Relations Genuino Christino – Group Chief Financial Officer Conference Call Participants Ephrem Ravi – Citi Alain Gabriel – Morgan Stanley Tom Zhang – Barclays Patrick Mann – Bank of America Andrew Jones – UBS Dominic O’Kane – JPMorgan Boris Bourdet – Boris Bourdet Tristan Gresser – BNP Paribas Matt Greene – Goldman Sachs Max Kogge – Oddo Bastian Synagowitz – Deutsche B ...

Financial Data and Key Metrics - Consolidated net sales revenue decreased by 7.8%, underlying pre-tax income decreased by 8.7%, and underlying earnings per share decreased by 6.2% in Q3 [8] - U.S. financial volume declined by 17.9%, and brand volume declined by 6.2% due to macroeconomic pressures [8] - Underlying free cash flow for the first nine months of the year was $856 million, with $717 million returned to shareholders through dividends and share repurchases [16] - The company adjusted its 2024 net sales revenue guidance to a decline of approximately 1%, down from previous low single-digit growth expectations [11] Business Line Performance - Core power brands in the U.S. (Coors Lite, Miller Lite, and Coors Banquet) saw a combined volume share decline of 0.5 points year-over-year, but retained significant share gains compared to 2022 [17] - Coors Banquet grew brand volume by 8% and gained industry share for the 13th consecutive quarter, making it the fastest-growing top 15 beer brand in the U.S. by volume percentage growth [17] - In Canada, Coors Lite gained segment share and remained the number one lite beer in the industry [18] - EMEA and APAC regions saw strong performance, with Ožujsko in Croatia growing volume by 6% and the successful relaunch of Caraiman in Romania, which reached over 250,000 hectoliters since March [19][20] Market Performance - The U.S. market faced challenges due to macroeconomic pressures, leading to value-seeking behavior and channel/pack shifting, particularly during the summer [10] - Canada and EMEA/APAC regions performed strongly, with Canada's top-line growth at 5.7% and EMEA/APAC also growing at 5.7% for the first nine months of 2024 [48][49] - The U.K. market saw soft consumer demand and increased promotional intensity, but Madri continued to drive volume and value growth [110][112] Company Strategy and Industry Competition - The company is focusing on premiumization, with over half of EMEA and APAC net brand revenue coming from above-premium products [21] - Investments in local production for Peroni in the U.S. aim to improve supply consistency and introduce new pack sizes, with plans to scale the brand significantly by 2025 [24][25] - The company increased its ownership stake in Zoa to 51%, aiming to leverage its network for marketing and distribution growth [27][28] - The company is divesting underperforming craft breweries to focus on scalable above-premium opportunities in the U.S. [23] Management Commentary on Operating Environment and Future Outlook - Management acknowledged the impact of macroeconomic pressures on the U.S. beer industry but expressed confidence in the long-term growth potential of the business [9][11] - The company reaffirmed its mid-single-digit growth guidance for underlying pre-tax income and narrowed its EPS guidance to the higher end of the range, supported by cost savings and share repurchases [11][12] - Management highlighted the importance of premiumization, innovation, and supply chain efficiencies in driving long-term profitable growth [32] Other Important Information - The company completed its multi-year Golden Brewery upgrade, providing more flexibility for future investments and cost savings [36] - Moody's upgraded the company's credit rating to BAA1 stable, the highest investment-grade rating in over a dozen years [37] - The company repurchased 7.5 million shares in the first nine months of 2024, utilizing 29% of its $2 billion share repurchase plan [39] Q&A Session Summary Question: Impact of shipment timing and macroeconomic pressures on U.S. financial volumes [52] - The decline in U.S. financial volumes was driven by a 17.9% drop in shipments, a 6.2% decline in brand volume, and a 2.6% impact from Pabst contract brewing [57] - The company expects a remaining headwind of 500,000 hectoliters in Q4 due to the termination of the Pabst contract [42] Question: Consumer behavior and industry trends [59] - The U.S. beer industry saw value-seeking behavior and channel/pack shifting during the summer, but trends improved in September and October [61][62] - Premiumization continues to be a key trend, particularly in the U.S. and Canada [63] Question: Shelf space retention and gains [66] - The company retained the significant shelf space gained in 2023 and achieved additional gains in the fall reset [69][70] Question: Marketing investment levels [71] - Marketing investment was down in Q3 compared to the prior year but is expected to be up for the full year 2024 [72][73] Question: Pricing and promotional environment [84] - Pricing remains in the historical range of 1% to 2%, with no significant changes in promotional activity except for deeper discounting in the above-premium tier [86][87] Question: Performance of Happy Thursday and flavor portfolio [88] - Happy Thursday has shown early positive results, particularly among Gen Z consumers, and the company plans to continue supporting the brand [92][93] Question: Plans for Blue Moon and Coors Banquet [95] - Blue Moon is showing signs of stability, with sequential improvement in total industry dollar share, while Coors Banquet continues to grow strongly [97][100] Question: COGS per hectoliter outlook [95] - The company expects cost savings from supply chain efficiencies and the removal of Pabst contract brewing to positively impact COGS [101][102] Question: Category trends and Q4 outlook [104] - The company has a good handle on Q4 drivers, including pricing and shipment trends, and remains confident in its long-term growth algorithm [105][107] Question: EMEA and APAC volume weakness [109] - Soft consumer demand in the U.K. and increased promotional intensity contributed to volume declines, but Madri continues to perform well [110][112] Question: Zoa's performance and future plans [114] - Zoa is gaining traction as a better-for-you energy drink, with strong performance on Amazon and new distribution opportunities [116][117]

Tapestry, Inc. (NYSE:TPR) Q1 2025 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Christina Colone - Global Head, Investor Relations Joanne Crevoiserat - Chief Executive Officer Scott Roe - Chief Financial Officer and Chief Operating Officer Todd Kahn - Chief Executive Officer and Brand President, Coach Conference Call Participants Bob Drbul - Guggenheim Securities Ike Boruchow - Wells Fargo Matthew Boss - JPMorgan Lorraine Hutchinson - Bank of America Michael Binetti - Evercore Ri ...

Dynatrace, Inc. (NYSE:DT) Q2 2025 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Noelle Faris - Vice President, Investor Relations Rick McConnell - Chief Executive Officer Jim Benson - Chief Financial Officer Conference Call Participants Pinjalim Bora - JPMorgan Sanjit Singh - Morgan Stanley Jake Roberge - William Blair Raimo Lenschow - Barclays Brad Reback - Stifel Andrew Sherman - TD Cowen Howard Ma - Guggenheim Securities Operator Greetings. Welcome to the Dynatrace Fiscal Seco ...

Himax Technologies, Inc. (NASDAQ:HIMX) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Eric Li - Chief IR and PR Officer Jordan Wu - President and Chief Executive Officer Jessica Pan - Chief Financial Officer Conference Call Participants Donnie Teng - Nomura Operator Hello, ladies and gentlemen. Welcome to the Himax Technologies Inc. Third Quarter 2024 Earnings Conference Call. At this time all participants are in listen only mode. Later we will conduct a question-and-answe ...

Financial Data and Key Metrics - Revenue for Q3 2024 was $1.9 billion, with net income of $13 million [7] - Cash and investments at the end of Q3 2024 totaled $9.2 billion, down from $10.8 billion at the end of Q2 2024 [32] - Operating expenses were reduced by $500 million year-over-year in Q3 2024, excluding a $1.4 billion charge from Q3 2023 [7] - Cost of sales declined by 77% year-over-year to $514 million in Q3 2024, driven by manufacturing productivity improvements [28] - R&D expenses decreased by 2% year-over-year to $1.1 billion in Q3 2024, excluding a priority review voucher purchase [29] - SG&A expenses decreased by 36% year-over-year to $281 million in Q3 2024, reflecting cost efficiency efforts [30] Business Line Performance - Spikevax (COVID-19 vaccine) achieved a 40% market share in the U.S. retail market for the 2024-2025 season [9] - RSV vaccine (mRESVIA) sales were $10 million in Q3 2024, below expectations due to late approval and competitor inventory buildup [14] - The company expects to increase RSV market share in 2025 with full participation in the contracting season and potential label expansion [15] Market Performance - U.S. market contributed $1.2 billion in product sales in Q3 2024, driven by an earlier vaccine launch and a $140 million provision release [23] - International sales were $0.6 billion in Q3 2024, in line with expectations but lower than the same period in 2023 [25] - The company expects Q4 2024 U.S. product sales to range between $200 million and $500 million, and international sales between $600 million and $800 million [25][27] Strategy and Industry Competition - The company aims to drive COVID vaccination rates closer to flu vaccination rates, particularly in under-penetrated channels like IDNs and government programs [11][13] - Moderna is focusing on educating healthcare providers and consumers about the benefits of COVID vaccination, including reducing the risk of long COVID [12][13] - The company plans to expand its manufacturing footprint in the U.K., Canada, and Australia in 2025 to fulfill multi-year contracts [53] Management Commentary on Operating Environment and Future Outlook - The COVID market is expected to remain a sizable and durable long-term market, with Moderna well-positioned to capture growth [9] - The company is optimistic about the potential for RSV market expansion, particularly with international approvals and potential revaccination recommendations [15] - Moderna is committed to improving cost efficiencies, with a goal to reduce annual R&D expenses by $1.1 billion by 2027 [55] Other Important Information - The company expanded its executive committee, promoting internal talent and emphasizing the integration of digital technology and AI [18][19] - Moderna expects to file for approval of three products in 2024: next-gen COVID vaccine, RSV vaccine for high-risk individuals, and a combination COVID-flu vaccine [54] Q&A Session Summary Question: Rest of world revenue and CMV interim analysis [58] - Rest of world revenue in Q3 2024 was driven by orders from the U.K., Canada, Australia, and Brazil, with most of the $600 million in Q4 expected from contracted volumes [59][60] - For CMV, if the DSMB recommends un-blinding at the interim analysis, the company will share the results; otherwise, it will wait for the final analysis [61] Question: Ex-U.S. COVID revenue contracts and CMV accrual timing [63] - The company has multi-year contracts with some countries, with revenue expected to decline in 2025 before increasing in 2026 [65] - CMV case accrual is steady, and the final analysis could happen quickly after the interim analysis [66] Question: U.S. pricing, reserve returns, and flu-COVID combo [69] - U.S. pricing for COVID vaccines is approximately $63 per dose, and reserve returns for the 2023-2024 season were adjusted to $400 million [70][75] - The company decided not to use a priority review voucher for the flu-COVID combo due to timing constraints, with potential approval in 2025 [71][72] Question: RSV market dynamics and COVID market share [78][107] - The RSV market has been slower than expected, with inventory buildup and delayed CDC guidelines impacting sales [81][82] - Moderna lost some market share in the U.S. retail COVID market but expects to gain a clearer picture of overall market share by the end of the season [108] Question: INT program and manufacturing [90] - The INT manufacturing facility in Massachusetts is on track for completion by year-end, with no bridging work required for FDA approval [91][92] Question: Election impact and RSV international expansion [94] - The company is confident in its ability to work with any administration to advance public health goals [96] - RSV market expansion outside the U.S. is expected to grow, but timing depends on regulatory approvals and pricing negotiations [97][98] Question: Orphan disease pipeline [102] - Pivotal trials for MMA and PA are expected to start in 2025, with potential launches in 2026 or later, depending on enrollment and trial progress [103][104] Question: Flu-COVID combo transition and COVID litigation [118] - The flu-COVID combo is not expected to transition the market in 2025 due to contracting timing, with potential impact in 2026 [119][120] - The company is prepared to defend against GSK's lawsuit, which is common during market formation around new technologies [122]